Study Highlights Need for Molecular Guidance in Atopic Dermatitis Treatment

A study was announced at the National Eczema Association Expo regarding atopic dermatitis (AD) treatment. The findings showed that more than half of patients who used targeted systemic therapies modified their treatment due to lack of efficacy. Among patients surveyed who were open to a new systemic therapy, 94% expressed interest in molecular testing to help identify a more effective treatment.

The study supports the clinical need for molecular guidance in AD care. The findings highlight the potential of the AdvanceAD-Tx test to help personalize systemic therapy decisions by incorporating objective molecular information into patient care conversations.